Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology
JCO Precision Oncology · 2026-07 · 10 (7)
DOI: 10.1200/po-26-00158 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Sophia C Kamran und 30 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center, Boston, MA. Hauptthemen laut MEDLINE: Biological Specimen Banks, Precision Medicine, Prostatic Neoplasms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Precision medicine has revolutionized oncology; however, tumor biomarkers are not reflective of the heterogeneous cancer population. We evaluated NRG Oncology prostate cancer (PCa) clinical trials for demographic differences among patients with optional biospecimen collection (BC) consent and biospecimen submission (BSub). METHODS Data from 19 NRG PCa clinical trials closed before 2015 were analyzed. Patients who consented to BC and completed BSub were evaluated by race, ethnicity, median income, area deprivation index (ADI; categorized as highest v lowest three quartiles), age at enrollment, site, and year of enrollment. T/chi-square tests were used for continuous/categorical variables, respectively, followed by logistic regression. RESULTS Of the 15,648 randomized patients eligible for BC, 11,796 (75%) had specimens submitted. In all, 4,598 (82.2%) of 5,597 eligible patients consented for optional BC in nine clinical trials with a separate BC consent process (consent rates by race/ethnicity: 74.1% Black, 72.8% Hispanic/Latino, 83.8% White). A smaller proportion of Black and Hispanic/Latino patients consented to optional BC compared with those who did not (12.1% v 19.5% Black, P < .0001; 3.5% v 5.8% Hispanic, P = .0006). In univariable logistic regression models, high ADI (more socioeconomic disadvantage) was associated with a decreased likelihood for optional BC consent (odds ratio [OR], 0.67 [95% CI, 0.55 to 0.82]; P = .02), but not a decreased likelihood for BSub (OR, 0.74 [95% CI, 0.53 to 1.04]; P = .08). Multivariable models demonstrated that Black/Hispanic/Latino patients were less likely to consent to optional BC, and Black patients were less likely to have BSub ( P < .05 for all). CONCLUSION White/non-Hispanic patients and those with less socioeconomic disadvantage were more likely to consent to optional BC, whereas Black patients were less likely to have BSub. Targeted solutions are needed to improve biorepository representation so that precision medicine approaches better reflect the cancer population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Massachusetts General Hospital Cancer Center, Boston, MA.
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
- American College of Radiology, Philadelphia, PA.
- Washington University School of Medicine, Saint Louis, MO.
- Duke University Medical Center, Durham, NC.
- Cedars-Sinai Medical Center, Los Angeles, CA.
ORCID-Profile: Sophia C Kamran, Jeff Michalski, W Robert Lee, Howard M Sandler, Juanita Crook, Alan Pollack, Deborah Watkins Bruner, Christopher U Jones, Mack Roach, Jason Efstathiou, David Miyamoto, Melissa Vyfhuis, Quynh-Thu Le, Eliezer Van Allen, Jean-Paul Bahary, Jennifer Wenzel, Phuoc Tran
Förderung
- NCI NIH HHS
Zitieren
APA
Kamran, S. C., Borges, M., Michalski, J., Lee, W. R., Sandler, H. M., Crook, J., Pollack, A., Hurwitz, M. D., Valicenti, R. K., Bruner, D. W., Lukka, H., Jones, C. U., Roach, M., Lawton, C., Rosenthal, S. A., Pisansky, T. M., Spratt, D., Vapiwala, N., Efstathiou, J., …, & Tran, P. (2026). Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-26-00158
Vancouver
Kamran SC, Borges M, Michalski J, Lee WR, Sandler HM, Crook J, et al. Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-26-00158
BibTeX
@article{Kamran2026,
author = {Kamran, Sophia C and Borges, Monica and Michalski, Jeff and Lee, W Robert and Sandler, Howard M and Crook, Juanita and Pollack, Alan and Hurwitz, Mark D and Valicenti, Richard K and Bruner, Deborah Watkins and Lukka, Himanshu and Jones, Christopher U and Roach, Mack and Lawton, Colleen and Rosenthal, Seth A and Pisansky, Thomas M and Spratt, Daniel and Vapiwala, Neha and Efstathiou, Jason and Miyamoto, David and Mouw, Kent and Vyfhuis, Melissa and Le, Quynh-Thu and Willers, Henning and Van Allen, Eliezer and Huang, Franklin and Bahary, Jean-Paul and Helou, Joelle and Pugh, Stephanie L and Wenzel, Jennifer and Tran, Phuoc},
title = {Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {7},
doi = {10.1200/po-26-00158}
}
EUVIMED